Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis Clinical Trial

Official title:

A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02197767
• Other study ID #: 13-006694
• Status: Completed
• Phase: Phase 2
• Start date: November 2014
• Est. completion date: April 2017

Study information

• Verified date: January 2019
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.

Description:

This is a Phase II, open-label pilot study to determine if the use of Rituximab reduces proteinuria over a 12 month period and is there preservation of kidney function with the use of this study drug. Each patient will be treated with 2 intravenous infusions of rituximab 1000 mg, two weeks apart for a total of 2 doses. Each patient will be retreated with identical 2 intravenous infusions of rituximab, two weeks apart at 6 months after the first infusion, irrespective of cluster of differentiation (CD) 20+ cell counts. Thus, each participant will receive 4 infusions of rituximab.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Fibrillary Glomerulonephritis with diagnostic biopsy performed within the last 2 years

• Proteinuria >1 gram

• Age > 18 years but < 80 years

• Adequately controlled blood pressure (BP<140/90 mmHg in >75% of the readings) for at least 3 months prior to enrollment with the use of (angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin-receptor blockers (ARB), if tolerated.

• Women must be post- menopausal, surgically sterile or practicing a medically approved method of contraception

• Able and willing to give written informed consent and comply with the requirements of the study protocol

• Adequate renal function as indicated by estimated glomerular filtration rate (GFR) > 25 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD/EPI) formula or a quantified creatinine clearance >25 mL/min, and/or serum creatinine <3.0 mg/dL in the presence of ACEi/ARB therapy

• Adequate bone marrow function, as indicated by hemoglobin >7.0 gm/dL, white count >3.0 x 10(9), platelet count >100 x 10(9)

• Negative chest x-ray within one year

• Negative serum pregnancy test (for women of child bearing age)

• Normal organ function.

• Subject agrees to use an acceptable method of birth control during treatment and for twelve months after completion of treatment

• Subject has provided written informed consent

• Subject agrees to discontinue routine use of non-steroidal anti-inflammatory drugs

• Absolute Neutrophil Count (ANC): > 1000/ mm3

• Adequate liver function, as indicated by aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and total bilirubin < 2x upper limit or normal unless related to primary disease

• Negative HBsAg and anti-hepatitis B (HBc) lab values within 1 year of signing consent

Exclusion Criteria:

• Pregnancy (determined by a serum pregnancy test for all women of childbearing potential within 7 days of treatment), or lactating.

• Inability to comply with study and/or follow-up procedures

• History of HIV (a documented positive lab value within one year of enrollment)

• Presence of active infection

• New York Heart Association Classification III or IV heart disease

• Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

• History of psychiatric disorder

• At the Investigator's discretion, receipt of a live vaccine within 4 weeks prior to randomization

• At the Investigator's discretion, positive Hepatitis C serology

• Known history of diabetes mellitus or a Hemoglobin A1c result > 6.0% within 90 days prior to enrollment

Related Conditions & MeSH terms

• Fibrillary Glomerulonephritis
• Glomerulonephritis

Intervention

Drug:
• rituximab
1000 mg infusion

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 24 Hour Creatinine Clearance	Change in 24 hour creatinine clearance with the use of rituximab at 12 months. Creatinine clearance results are reported as milliliters/minute/patient's body surface area (mL/min/SA).	Day 0, Day 365
Secondary	Change in Proteinuria	Change in proteinuria in milligrams (mg) with the use of rituximab at 12 months.	Day 0, Day 365